Literature DB >> 11156872

Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia.

A Kawamoto1, H C Gwon, H Iwaguro, J I Yamaguchi, S Uchida, H Masuda, M Silver, H Ma, M Kearney, J M Isner, T Asahara.   

Abstract

BACKGROUND: We investigated the therapeutic potential of ex vivo expanded endothelial progenitor cells (EPCs) for myocardial neovascularization. METHODS AND
RESULTS: Peripheral blood mononuclear cells obtained from healthy human adults were cultured in EPC medium and harvested 7 days later. Myocardial ischemia was induced by ligating the left anterior descending coronary artery in male Hsd:RH-rnu (athymic nude) rats. A total of 10(6) EPCs labeled with 1,1'-dioctadecyl-1 to 3,3,3',3'-tetramethylindocarbocyanine perchlorate were injected intravenously 3 hours after the induction of myocardial ischemia. Seven days later, fluorescence-conjugated Bandeiraea simplicifolia lectin I was administered intravenously, and the rats were immediately killed. Fluorescence microscopy revealed that transplanted EPCs accumulated in the ischemic area and incorporated into foci of myocardial neovascularization. To determine the impact on left ventricular function, 5 rats (EPC group) were injected intravenously with 10(6) EPCs 3 hours after ischemia; 5 other rats (control group) received culture media. Echocardiography, performed just before and 28 days after ischemia, disclosed ventricular dimensions that were significantly smaller and fractional shortening that was significantly greater in the EPC group than in the control group by day 28. Regional wall motion was better preserved in the EPC group. After euthanization on day 28, necropsy examination disclosed that capillary density was significantly greater in the EPC group than in the control group. Moreover, the extent of left ventricular scarring was significantly less in rats receiving EPCs than in controls. Immunohistochemistry revealed capillaries that were positive for human-specific endothelial cells.
CONCLUSIONS: Ex vivo expanded EPCs incorporate into foci of myocardial neovascularization and have a favorable impact on the preservation of left ventricular function.

Entities:  

Mesh:

Year:  2001        PMID: 11156872     DOI: 10.1161/01.cir.103.5.634

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  262 in total

1.  Cardiomyocytes induce endothelial cells to trans-differentiate into cardiac muscle: implications for myocardium regeneration.

Authors:  G Condorelli; U Borello; L De Angelis; M Latronico; D Sirabella; M Coletta; R Galli; G Balconi; A Follenzi; G Frati; M G Cusella De Angelis; L Gioglio; S Amuchastegui; L Adorini; L Naldini; A Vescovi; E Dejana; G Cossu
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-04       Impact factor: 11.205

2.  Thymosin beta4: a key factor for protective effects of eEPCs in acute and chronic ischemia.

Authors:  Rabea Hinkel; Ildiko Bock-Marquette; Antonis K Hatzopoulos; Antonis K Hazopoulos; Christian Kupatt
Journal:  Ann N Y Acad Sci       Date:  2010-04       Impact factor: 5.691

3.  Interactions between endothelial progenitor cells (EPC) and titanium implant surfaces.

Authors:  Thomas Ziebart; Anne Schnell; Christian Walter; Peer W Kämmerer; Andreas Pabst; Karl M Lehmann; Johanna Ziebart; Marc O Klein; Bilal Al-Nawas
Journal:  Clin Oral Investig       Date:  2012-03-10       Impact factor: 3.573

4.  Statin therapy: having the good without the bad.

Authors:  James K Liao
Journal:  Hypertension       Date:  2004-06       Impact factor: 10.190

5.  SDF-1α and CXCR4 as therapeutic targets in cardiovascular disease.

Authors:  Jessica Wen; Jian-Qing Zhang; Wei Huang; Yigang Wang
Journal:  Am J Cardiovasc Dis       Date:  2011-12-15

Review 6.  Revisiting cardiovascular regeneration with bone marrow-derived angiogenic and vasculogenic cells.

Authors:  Sangho Lee; Young-Sup Yoon
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

7.  Bone marrow derived stem cells in regenerative medicine as advanced therapy medicinal products.

Authors:  Giuseppe Astori; Sabrina Soncin; Viviana Lo Cicero; Francesco Siclari; Daniel Sürder; Lucia Turchetto; Gianni Soldati; Tiziano Moccetti
Journal:  Am J Transl Res       Date:  2010-05-15       Impact factor: 4.060

Review 8.  Resident vascular progenitor cells--diverse origins, phenotype, and function.

Authors:  Peter J Psaltis; Adriana Harbuzariu; Sinny Delacroix; Eric W Holroyd; Robert D Simari
Journal:  J Cardiovasc Transl Res       Date:  2010-11-30       Impact factor: 4.132

9.  Dual angiogenic and neurotrophic effects of bone marrow-derived endothelial progenitor cells on diabetic neuropathy.

Authors:  Jin-Ok Jeong; Mee-Ohk Kim; Hyongbum Kim; Min-Young Lee; Sung-Whan Kim; Masaaki Ii; Jung-uek Lee; Jiyoon Lee; Yong Jin Choi; Hyun-Jai Cho; Namho Lee; Marcy Silver; Andrea Wecker; Dong-Wook Kim; Young-sup Yoon
Journal:  Circulation       Date:  2009-01-26       Impact factor: 29.690

10.  Tachycardia pacing induces myocardial neovascularization and mobilizes circulating endothelial progenitor cells partly via SDF-1 pathway in canines.

Authors:  Jingting Mai; Fei Wang; Qiong Qiu; Buzhou Tang; YongQing Lin; NianSang Luo; WoLiang Yuan; XiaoLong Wang; Qingcai Chen; JingFeng Wang; YangXin Chen
Journal:  Heart Vessels       Date:  2014-12-10       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.